罕见病药物氨己烯酸片有副作用吗

An orphan drug (vigabatrin) is available for adults and children (10 years and older) with refractory complex partial seizures (CPS, also known as focal seizures). People who are severely allergic to vigabatrin tablets (vigabatrin) or any excipients in the drug are prohibited from taking it.

Does the rare disease drug vigabatrin tablets have side effects?

According to clinical trials, vigabatrin tablets (vigabatrin) have significant therapeutic effects, but taking this drug for treatment will also produce certain side effects or adverse reactions. Common ones include: fatigue/drowsiness/headache/dizziness/mental confusion/depression, etc. Before receiving treatment with vigabatrin, patients should go to the hospital for detailed testing and take medication strictly according to the doctor's diagnosis and treatment recommendations. The use of vigabatrin tablets (vigabatrin) should be done under the guidance of an epilepsy expert or a child neurologist. Reactions after taking the medication should be reported to the doctor promptly.

Patients who are treated with vigabatrin tablets (vigabatrin) should pay attention to:

The incidence of visual field defects is high (approximately one third) in patients taking vigabatrin. This often occurs after several months to years of using vigabatrin. Visual field defects can be severe, which can have real consequences for the patient. Most patients with visual field loss have no obvious symptoms.

Taking vigabatrin for treatment may affect your ability to drive and use machinery. Generally, patients with uncontrolled epilepsy are not allowed to drive or operate potentially dangerous machinery. In view of reports of drowsiness during clinical use of vigabatrin, patients should be warned before initiating treatment with this drug.

The above is the introduction about (vigabatrin), I hope it can help everyone. If patients have other questions about the drug (such as drug price, purchasing channels, etc.), they can consult the medical companion travel service.

Recommended related hot articles: /newsDetail/82911.html